LDS/Medical Tests/Low Density Lipoprotein (LDL, VLDL)

Low Density Lipoprotein (LDL, VLDL)

Lipids are transported in the bloodstream by five major groups of lipoproteins. From largest to smallest they are: chylomicrons, VLDL, IDL, LDL, and HDL. The majority of cholesterol stored in atherosclerotic plaques originates from LDL. It is the most powerful clinical predictor among all of the single parameters with respect to atherosclerosis. Since LDL is a key factor in the progression of atherosclerosis and coronary sclerosis, it is referred to as the “bad cholesterol” particles.

LDLs are derived from VLDLs (Very Low Density Lipoproteins) rich in triglycerides by the action of lipolytic enzymes and are synthesized in the liver. Excessive amounts of circulating LDL particles may be taken up by macrophages (foam cells) as well as by smooth muscle cells in vessel walls, leading to atherosclerosis. Direct LDL quantitative values better reveal individual issues rather than mathematically calculated estimates. LDL is usually ordered as a part of a lipid profile that includes total cholesterol, High Density Lipoproteins (HDL), and triglycerides.

  • Aid in diagnosis of familial hypercholesterolemia
  • Diagnosis of Premature Coronary Heart Disease
  • Assessing individual risk of cardiovascular events

Increased in:

  • Hypothyroidism
  • Nephrotic Syndrome
  • Gammopathies
  • Anorexia nervosa
  • Diabetes mellitus
  • Chronic renal failure
  • Certain Drugs (e.g., estrogens, androgens, carbamazepine)

Decreased in:

  • Malnutrition
  • Intestinal malabsorption
  • Hyperthyroidism
  • Myeloproliferative disorders
  • Reye syndrome
  • Severe hepatocellular dysfunction
Adults (mg/dL / mmol/L)
Category mg/dL mmol/L
Optimal <100 <2.85
Near optimal <130 <3.37
Borderline high 130–159 3.37–4.12
High 160–189 4.14–4.90
Very high ≥190 ≥4.92

 

Children (mg/dL / mmol/L)
Category mg/dL mmol/L
Acceptable <110 <2.85
Borderline 110–129 2.85–3.34
High ≥130 ≥3.37

 

Therapeutic Goals
Risk Category mg/dL mmol/L
High risk (CHD or CHD risk equivalents) <100 <2.59
Moderately high risk (2 risk factors; 10-yr risk 10–20%) <130 <3.37
Moderate risk (2 risk factors; 10-yr risk 10%) <130 <3.37
Lower risk (0–1 risk factors) <160 <4.14
Enzymatic colorimetric.

Serum

Serum Red top preferred. Serum gel (SST) acceptable. 

Patient should be fasting 10-16 hours prior to collection of specimen. No alcohol consumption for 24 hours prior to draw. Note patient age and sex.

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Lipoprotein Electrophoresis, Homocysteine, NT-proBNP, Lipid Profile, Apolipoprotein A-1, Apolipoprotein B-100, C-reactive protein (CRP), VLDL-C (Very Low Density Lipoprotein Cholesterol), NMR Lipo profile, Liver panel.
2-6 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Curr Atheroscler Rep. 2011 Nov 23. [PMID: 22109348]
  • Geriatr Nurs. 2006 May-Jun;27(3):142-8. [PMID: 16757384]
  • J Am Acad Nurse Pract. 2003 Aug;15(8):350-60. [PMID: 14509100]
  • Mayo Clinic Proc. 2006;81:1225. [PMID: 16970219]
  • Med Gen Med. 2006;8:54. [PMID: 16915184]
  • Steven L. Jones. Clinical Laboratory Pearls. Philadelphia, PA, Lippincott Williams, and Wilkins (2001). Page 410.
  • Howanitz JH and Howanitz PJ. Laboratory Test Selection. New York, NY, Churchill Livingstone (1991). Pages 189-191.
  • Roche Diagnostics LDL package insert, V4, Indianapolis, IN, 2008, Page 1